🦉 The Night Owl Newsletter for August 24th

Visa placed Hims & Hers Health into its Acquirer Monitoring Program after a billing dispute spike, adding penalty costs amid an FTC lawsuit... ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe Buffett's Final Warning: "The Dollar Is Going to Hell" (From Decentralized Masters) Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters Written by Jeffrey Neal Johnson The telehealth sector relies heavily on frictionless subscription models to sustain top-line growth. When consumers find those subscriptions difficult to cancel, they bypass customer service and call their credit card providers. A recent surge in these chargebacks has forced a major global payment network to intervene in the operations of a leading virtual care provider. Visa Inc. (NYSE: V) recently placed Hims & Hers Health (NYSE: HIMS) into its Acquirer Monitoring Program following a spike in billing disputes. This action introduces an immediate financial penalty for every contested transaction, directly targeting the unit economics of the telehealth platform. For investors watching Hims & Hers Health gap down, the situation reveals a critical vulnerability: aggressive customer acquisition strategies can erode long-term profitability. Understanding the mechanics of this payment network penalty is essential for evaluating the forward guidance of consumer-direct medical platforms. Card Declined: Unpacking the Visa Penalty On the surface, the narrative around Hims & Hers Health centers on rapid expansion into new healthcare verticals. Beneath that growth, a fundamental friction is playing out. In late July, the Federal Trade Commission, joined by the attorneys general of California and Utah, filed a lawsuit alleging that Hims & Hers Health engaged in deceptive billing practices. The complaint alleges that the platform trapped users in recurring subscriptions by deliberately obscuring the cancellation process behind confusing interfaces. When consumers cannot easily click a button to stop a charge, they initiate a chargeback. Visa responded to this elevated dispute volume by triggering its Acquirer Monitoring Program. Every time a patient disputes a charge, Visa levies an $8 penalty. While an $8 surcharge might seem negligible against the backdrop of a multibillion-dollar valuation, it functions as a systemic tax on the revenue engine. The aggregate penalty, approaching roughly $75,000 for a single recent month, is less concerning than what it represents: a structural flaw in customer retention that regulators and payment networks are no longer willing to ignore. Subscription models rely on a delicate balance between customer acquisition costs and lifetime value. When chargebacks spike, that equation breaks down. Tollbooth Economics: Visa Wins While Hims Pays The immediate fundamental concern for investors is margin compression. Hims & Hers Health already reported a sharp contraction in gross margin in its second-quarter earnings, down to around 64% from roughly 76% a year prior. Adjusted earnings before interest, taxes, depreciation, and amortization guidance for the third quarter also landed on the softer side of analyst expectations, signaling that internal operational friction is already degrading profitability. To exit Visa's penalty box, Hims & Hers Health must suppress its dispute rate below 1.5% for three consecutive months. Doing so inherently requires introducing more friction into its high-speed customer acquisition funnel. Implementing clearer cancellation buttons, sending mandatory opt-in confirmations, and overhauling billing transparency naturally slows down subscriber momentum. These necessary compliance measures create a definitive drag on top-line growth. Any deceleration in subscriber additions forces the market to reprice the valuation multiple. Conversely, Visa remains entirely insulated. Visa's asset-light, tollbooth model allows it to maintain net margins hovering near 51%. Visa collects its standard processing fees along with newly imposed penalty surcharges, which are entirely unaffected by the regulatory turbulence shaking the telehealth space. Visa does not assume customer acquisition risk, yet it participates in every transaction, good or bad. Executive Ejection: Insiders Exit Before the Tolls When fundamental metrics begin to shift, tracking management's capital allocation provides essential context. The 12-month insider trading profile for Hims & Hers Health shows heavy distribution, registering nearly $60 million in annualized selling against negligible open-market purchases. Timing adds weight to these transactions. Payment processor Stripe reportedly notified Hims & Hers Health of its penalized status in early August. Shortly after that notification, the Chief Financial Officer liquidated over 14,000 shares through a series of block sales. Executives sell equity for many reasons, including tax obligations, pre-planned 10b5-1 programs, and routine diversification. However, large distributions clustered closely around undisclosed operational headwinds often signal internal capitulation regarding near-term margin stabilization. When the architects of a balance sheet reduce their exposure ahead of mounting compliance costs, the broader market takes notice. Investors should weigh this outflow against the upcoming earnings cycle, as executives will need to answer for these rising regulatory costs. The Peptide Fast Lane: A Bullish Bypass A purely bearish outlook ignores the structural tailwinds that can overpower these payment-processing friction costs. Hims & Hers Health has experienced a strong revenue surge driven by its aggressive rollout of compounded GLP-1 weight-loss peptides. This segment operates in a complex, highly lucrative regulatory environment dependent on federal drug shortage classifications. The Food and Drug Administration allows compounding pharmacies to recreate branded medications when the original drugs are in national shortage. Should the regulatory landscape shift favorably, or if Hims & Hers Health successfully scales its customized peptide offerings without federal interference, the resulting top-line expansion could easily dwarf the Visa penalties. The underlying demand for GLP-1 alternatives remains staggering. Hims and Hers' stock trades at a price-to-sales ratio just over 3, indicating the market is still pricing in sustained, aggressive growth. Any positive regulatory catalyst surrounding the peptide pipeline possesses the precise characteristics needed to ignite a rapid short squeeze. Traders heavily shorting the equity based solely on the billing dispute narrative face high binary risk if the compounding pharmaceutical division receives a clear regulatory runway. Pick a Lane: Infrastructure Vs. Growth Market participants currently face a polarizing environment. The fundamental short thesis relies on impending compliance costs, elevated processing fees, and the systemic drag of a Federal Trade Commission lawsuit eroding free cash flow. If Hims & Hers Health struggles to lower its dispute rate without throttling new customer additions, downward revisions to forward revenue guidance become increasingly possible. On the other side of the trade, the compounded weight-loss pipeline offers explosive upside optionality that routinely defies standard valuation models. Investors might view this environment as a reason to stay on the sidelines until a clearer trend emerges in the upcoming earnings cycle. Those seeking exposure to the overarching digital economy without the regulatory risk often gravitate toward the infrastructure layer. Holding a payment network like Visa allows investors to benefit from transaction volume across the entire consumer health sector, collecting consistent tolls regardless of which individual telehealth platform wins the market share battle. Evaluating both the friction of the penalty box and the promise of the peptide pipeline will be critical for anyone allocating capital in this space. Read This Story Online This under $1 stock could become Musk's next supplier (Ad) A little-known company trading under $1 could become Elon Musk's next supplier, with a possible announcement expected by Wednesday, August 26. Tech investing veteran Jeff Brown notes that the last time Musk struck a deal with a small company in this sector, the stock soared nearly five times in a single session. He has reopened his strategy session with full details on this potential opportunity. Watch Jeff Brown's urgent strategy session before the Wednesday deadline Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain Written by Chris Markoch Long-term Treasury yields are rebounding despite the government's expanded bond-buyback plan, putting renewed pressure on rate-sensitive stocks. The 30-year recently reached its highest yield since 2007, prompting the U.S. Treasury Department to announce expanded long-duration buybacks to relieve pressure on the long end of the bond market. Yields bounced right back anyway. That's a sign that buyback programs alone may not be enough to keep a lid on borrowing costs. To be fair, bond yields don't move stock prices directly. But they move the assumptions investors use to price stocks, and that's where the real damage, or opportunity, happens. It's accurate to note that 30-year yields are not high in historical terms. But the long arc of history doesn't mean much to investors, consumers and businesses that became accustomed to operating in a world where low yields were expected. When financing costs stay elevated, businesses sensitive to dividends, growth, and momentum get repriced first, often before their actual earnings show any strain. The key is to understand how higher bond yields could impact specific stocks and sectors. Because the risks are different, but equally real. Realty Income: The Monthly Income Payer May Get Comparison Shopped Realty Income (NYSE: O) is known as The Monthly Dividend Company®. As a real estate investment trust (REIT), the company is required to pay out at least 90% of its earnings to shareholders as a dividend. The predictability of that dividend is also matched by an attractive 5.25% yield. However, Realty Income has also delivered attractive share price growth despite a challenging commercial real estate market. That's why Realty Income has delivered a total return of over 640% in the last 20 years. Higher long-term interest rates may start to make Realty Income's dividend look less competitive. That could change if the company continues to deliver double-digit stock price growth. That will depend on earnings, which may come under pressure if higher long-term bond yields elevate the company's financing costs. Analysts forecast approximately 3.8% earnings growth over the next 12 months. That's consistent with its earnings growth rate over the last 10 years, which may make it more attractive for current shareholders to hang on to their shares. However, investors on the sidelines may want to wait for confirmation of that earnings growth before committing capital. D.R. Horton: A Direct Correlation With a Frozen Housing Market D.R. Horton (NYSE: DHI) is one of the nation's largest homebuilders. It may surprise investors to see that DHI is up nearly 55% over the last five years despite a housing market that seized up once interest rates started to move higher. Homebuilders are not only dealing with soft consumer demand, but also with higher input costs. Theoretically, higher bond yields could lead to actions that bring inflation down. That would help with the input cost issue. But the demand problem will only be solved by lower mortgage rates, which are inconsistent with higher Treasury yields. This has shown up in the company's earnings per share (EPS), which are down year over year (YOY) for the past four quarters. In a higher-for-longer rate environment, D.R. Horton will likely have to rely on more promotions. That will put pressure on margins. Adding to that pressure, the homebuilder cut its forward revenue guidance when it reported Q3 2026 earnings in July. Bullish analysts point out that Berkshire Hathaway recently took a new stake in DHI. The company, formerly led by Warren Buffett, tends to be early. Skeptics will say Berkshire may be too early on this one. Palantir: Yields May Be the Immovable Object to Block Momentum Palantir Technologies (NASDAQ: PLTR) delivered one of the strongest earnings reports of the current cycle on Aug. 3. PLTR is up over 40% since the report after the company demonstrated its key role in the AI ecosystem. By every measure that matters, Palantir delivered a strong report. But its momentum has stalled around $170. That is due in no small part to higher Treasury yields. On the one hand, that just confirms a higher floor, which was likely and deserved after the strong report. On the other hand, the resistance to move higher could be attributed, in part, to higher yields, which are prompting investors to rethink risk-on assets with high valuations. The takeaway for investors is that it may take a period of multiple compressions for PLTR to move higher. That scenario would be a gift to many investors who were late to Palantir, as analysts continue to raise their price targets despite the valuation concerns. Read This Story Online Buffett's Final Warning: "The Dollar Is Going to Hell" (Ad) On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses. Watch how to protect yourself from what Dalio and Buffett see coming (free training). MongoDB Is Surging—And the Next Catalyst Is Almost Here Written by Thomas Hughes After years of struggling to gain traction, with numerous false starts and subsequent corrections, MongoDB (NASDAQ: MDB) has finally turned the tide. The stock price drifted lower in late spring, touched its long-term 150-week exponential moving average, and has been surging ever since. The takeaway: long-term buy-and-hold investors, short-term traders, and speculators are gobbling up shares. Analysts' activity reflects a bullish market posture, with an aggressive series of forecast revisions since the late-May release. These revisions strengthen the consensus and are leading this market to fresh highs. Investors can assume high conviction in the outlook, with 24 of the 36 analysts tracked issuing revisions or initiating coverage since May 29, an 80% Buy-side bias in the data, and an uptrend in price targets. Consensus assumes fair value near the top of the long-term range, but the trend is clear: consensus is up more than 15% over the period, with a high-end price target of $560. MongoDB Atlas Changed the Narrative: MDB Is AI-Critical for Inference MongoDB’s Atlas platform is a game-changing event for the company's cloud-native business. It transformed the business from a simple database provider into an automated, unified, cross-cloud data platform. Its tools help automate developer workflows, enabling them to do their primary job, write code, instead of all the back-end management that wastes so much time. Other advantages include native AI and vector searches, native multicloud functionality, and autoscaling, which preclude the need for multiple vendors and patchwork solutions. MDB enables businesses and enterprises to securely share sensitive, real-time information with agents and models for better contextualization and inference outcomes, and it is now entrenched in the AI ecosystem. MongoDB is native across hyperscale environments and has deepening relationships with several major hyperscalers. They are, in effect, part of the sales team, pushing MDB services because they drive use of the underlying cloud platforms. Price Action Points to Fresh Highs by Year’s End MongoDB’s recent price spike is significant because it sets the stage for a bigger gain. The push above $470 set a long-term high, and the stock now shows signs of consolidation, likely to be confirmed following the company's fiscal Q2 release in early September. Analysts are forecasting another strong quarter and are likely to be surprised to the upside, given the Q1 results. Not only did top-line growth accelerate versus the prior year and outperform consensus, but guidance also increased, and the remaining performance obligation (RPO) suggests caution in the outlook. RPO increased by 88%, more than 3x the Q1 revenue growth and the same as the forecast for fiscal Q2. In this scenario, a significant catalyst is in the works that could drive the market to a new high and keep analysts bullish. Technically, the price action suggests $130 of upside upon a break of the consolidation range, with as much as $180 at the high end. This would put MDB stock in the $600 to $650 range. MongoDB’s Price Rally Has Legs Institutional activity is another signal that this move has legs. The group owns nearly 90% of the stock and has been aggressively accumulating. More importantly, the data show accumulation accelerating in early Q3 2026 ahead of the report, aligning with the cue from analysts. This group is driving price action, limiting downside risk in August. The likely outcome is that they continue to limit risk in the coming quarters, potentially accelerating the rally if results are as strong as trends suggest. MongoDB’s biggest risk this year is its valuation. Trading near long-term highs, the stock is about 70x its current-year outlook and 40x the five-year forecast, pricing in significant growth. This opens the door to execution risk, quarterly weakness, or a slowdown in growth that could impair price action. Delays, missteps, or disruptions will show up in the stock price action, most likely as a deep correction. Competition is also a risk, but MongoDB's differentiated services and impact on hyperscaler business mitigate it; hyperscalers may prefer to sell their own databases, but are just as happy to give clients access to MongoDB when it drives business for their clouds. MongoDB’s balance sheet raises no red flags. The company has a solid cash position, ample liquidity, no long-term corporate debt, and improving cash flow. The likely outcome is that the company can continue to execute its strategy, convert backlog into revenue, and build on its momentum. As it stands, major catalysts in 2027 and 2028 are linked to the data center buildout. Most major data centers tied to the AI boom are slated for completion by then, at which point MDB will start generating revenue from that activity. Read This Story Online [EMERGENCY] The last time a country hit this debt level... (Ad) When Greece collapsed... the EU and IMF swooped in with $300 billion in bailouts. When America crosses that line... there is no bigger economy to save us. The U.S. IS the emergency bailout for the rest of the world. In a free presentation I just recorded, I show you exactly what the U.S. government's plan is... Why it's going to create the single biggest wealth transfer of our generation... and how you can position yourself on the right side of it. We believe America's only escape from $39 trillion in debt depends on a single technology (and it's already being funded with $2 trillion) ... BlackRock, Goldman, and 170 public companies are already positioning. Watch the free AI briefing (urgent) → More Stories What Rising Delivery Forecasts Say About Rivian's Stock Prospects Marvell Takes a Shot a Broadcom's Throne With Google Deal ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad) Walmart and Home Depot Earnings Show the K (Shaped Economy) Is Here to Stay 3 Dividend Stocks Raising Their Payouts as Investors Search for Growth and Income If Boeing Ramps Up Production, These Suppliers May Win Big BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish Setup The Night Owl is a financial newsletter that provides in-depth market analysis on stocks of interest to individual investors. Published by MarketBeat and Early Bird Publishing, The Night Owl is delivered around 9:00 PM Eastern Sunday through Thursday. If you give a hoot about the market, The Night Owl is the newsletter for you. View as a Web Page     If you have questions about your subscription, don't hesitate to contact our U.S. based support team at contact@marketbeat.com.   Unsubscribe   © 2006-2026 MarketBeat Media, LLC. All rights reserved. 345 N Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103. United States of America..   Read More: This Gold Explorer Sits Right Next to Barrick's Nevada Mines (From Wall Street Logic)

BSEM Expands Into Hospital Wound Care After Nasdaq Listing

BioStem Technologies now trades on Nasdaq as its hospital footprint and clinical pipeline continue to expand ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe A message from our friends at Trading Wire This has been disseminated on behalf of BioStem Technologies. From Regenerative Medicine Company to MedTech Contender: BSEM’s Nasdaq Debut Could Be Just the Starting Point! BioStem Technologies (NASDAQ: BSEM) is entering a higher-visibility phase after making the move to Nasdaq, giving the company access to a broader investment audience while it works to scale an increasingly diversified regenerative medicine and wound-care business. But the bigger story may be what BSEM has built behind the scenes. The BioTissue acquisition expanded the company into hospital-based surgical and acute wound care, bringing the Neox® and Clarix® product portfolios, GPO relationships and a significantly larger commercial operation. BioTissue generated approximately $29 million in 2025 revenue, while BSEM has expanded its direct sales force to 35 representatives. With unit volumes reportedly growing 40% year over year despite pricing pressure, the company is working to build a larger commercial engine across chronic wounds, surgery, burns and soft-tissue repair. Technology and clinical development provide another potential layer to the story. BSEM’s proprietary BioREtain® platform supports products including VENDAJE®, VENDAJE AC®, VENDAJE OPTIC® and AmnioWrap2™, while company-reported clinical data has provided evidence supporting its regenerative medicine approach. Meanwhile, ongoing studies involving diabetic foot ulcers and venous leg ulcers, potential Section 351 BLA pathways and evolving reimbursement dynamics could create additional catalysts as the wound-care industry continues to change. BSEM has already completed the Nasdaq transition; the focus now shifts toward integration, scaling, clinical progress and execution. BSEM may be a name worth keeping on the radar! See how BSEM is building a broader MedTech platform with hospital expansion, proprietary technology and multiple potential catalysts for growth ahead Exclusive Content 5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here's Why By Ryan Hasson. Publication Date: 8/24/2026. Key Points MarketBeat's five most-upgraded stocks over the past 90 days are all software companies, including Snowflake, Okta, Datadog, CrowdStrike, and Palo Alto Networks. Analysts cite these companies' ability to directly monetize the AI boom, through consumption-based data platforms, AI agent identity security, and cloud observability, as the driver of upgrades. All five stocks have posted strong year-to-date gains and carry consensus Moderate Buy ratings, but several trade near price targets ahead of upcoming earnings that could test valuations. Special Report: Forget SpaceX, Elon Is Now Powering the Next Hot IPO (From Brownstone Research) When analysts collectively raise their price targets and ratings on a single group of stocks, it pays to take notice. Upgrades reflect where Wall Street's research desks see earnings power and momentum heading next. When those upgrades cluster around one theme, they could mark the early stage of a leadership rotation. Right now, something worth flagging is happening on MarketBeat's most-upgraded stocks list: The five names drawing the most analyst enthusiasm over the past 90 days are all software companies. This is not entirely coincidental. After a brutal stretch earlier in the year, when software badly lagged the AI hardware trade, the group has come roaring back. The iShares Expanded Tech-Software Sector ETF (BATS: IGV) has climbed about 9.65% over the past quarter, comfortably outpacing the broader S&P 500. This comes as capital has rotated out of crowded, expensive semiconductor, memory and neo-cloud names and into software companies that are now proving they can monetize AI in their own right. Forget SpaceX, Elon Is Now Powering the Next Hot IPO (Ad) Elon Musk is backing a new AI startup that's quietly growing faster than Tesla, SpaceX, and reportedly 23 times faster than Nvidia, according to Jeff Brown of Brownstone Research. The company recently filed paperwork for what could become the next major IPO on Wall Street. Investors can explore how to claim a pre-IPO stake for as little as $50 before shares go public. See the startup's name and pre-IPO details now The five names below sit at the center of that shift. Here's why analysts can't stop upgrading them. Snowflake: The Data Cloud Turning AI Into Consumption Snowflake (NYSE: SNOW) runs a cloud-based data platform that lets enterprises store, analyze and share massive volumes of data across every major public cloud. It has become one of the purest ways to play a simple reality: Artificial intelligence is only as good as the data feeding it, and analysts have taken notice. The stock is up about 51% year to date, and the upgrades keep coming. Just last week, Truist raised its price target to $375, well above the current price, while the consensus rating among 40 analysts is Moderate Buy. The overarching sentiment driving the narrative is fairly straightforward: Snowflake's consumption-based model means that as customers build and run more AI workloads, they consume more Snowflake, turning the AI boom into a direct revenue tailwind. With earnings just around the corner, due Sept. 2, analysts have been confidently lifting targets and ratings ahead of what many expect to be another strong quarter. Okta: The Identity Layer Finding a Second Wind Okta (NASDAQ: OKTA) is the leading independent provider of identity and access management, the software that controls who can log in to what across an organization's digital footprint. Long viewed as a mature, steady grower, the company has found a fresh catalyst in the AI era, as securing not only human identities but also autonomous AI agents has become a rapidly expanding need. That narrative and strategic shift have powered the stock to an almost 57% gain this year, and the analyst community has moved quickly, assigning it a consensus Moderate Buy rating. In the past week alone, JPMorgan raised its price target to $165, while Cantor Fitzgerald reaffirmed its Buy rating. Morgan Stanley and KeyCorp reiterated their Overweight ratings, with both price targets implying more than 27% upside. The company's improving profitability, paired with its emerging role in securing AI agents, has reframed what was once seen as a forgotten software name. The company is set to report its second-quarter results on Aug. 26, so investors can expect another round of analyst actions. Heading into the report, the stock has spent several months consolidating in the upper band of its 52-week range, with $130 acting as critical support and $156 as the major breakout level. Datadog: The Observability Leader Riding the Cloud Wave Datadog (NASDAQ: DDOG) provides cloud monitoring and observability, giving engineering teams real-time visibility into the health and performance of their applications and infrastructure. As enterprises pour money into AI and cloud workloads, the need to monitor those increasingly complex systems is growing alongside them, placing Datadog squarely in the flow. The stock has been a standout sector and industry performer, up about 73% year to date, and it carries the most attractive upside target in this group. The consensus rating among 45 analysts is Moderate Buy, with an average price target of $276.32, implying more than 17% upside from current levels. Datadog's Q2 2026 report on Aug. 6 beat expectations. Although the stock sold off after the report amid a stretched valuation, analysts have used the subsequent pullback to reiterate their conviction. The company reported earnings per share (EPS) of 65 cents, comfortably topping the estimate of 58 cents, while quarterly revenue grew 35.6% from the prior year, also beating estimates. CrowdStrike: The Cybersecurity Heavyweight Analysts Keep Backing CrowdStrike (NASDAQ: CRWD) is a dominant force in cloud-native cybersecurity, protecting endpoints, cloud workloads and identities through its Falcon platform. It has become an enterprise standard in an era when AI is enabling attacks at machine speed, and that structural tailwind has kept analysts firmly in its corner. Shares are up almost 64% year to date, and the company has continued to draw positive analyst action, including recent target raises tied to its new partnership with Cerebras (NASDAQ: CBRS) to accelerate its AI security capabilities. The consensus rating among 50 analysts—the deepest coverage in this group—is Moderate Buy. One honest flag is that, after its powerful run, the stock has pulled back and now trades near the consensus price target, suggesting that much of the near-term optimism may already be priced in. That setup could change soon, however, with earnings expected on Aug. 26 after the market closes. Expectations are high for CRWD, with the consensus estimate calling for an almost 26% year-over-year increase in earnings and about 23% growth in sales over the prior quarter. Palo Alto Networks: The Platform Giant at the Front of the Pack Palo Alto Networks (NASDAQ: PANW) is the world's largest pure-play cybersecurity company, consolidating firewalls, cloud security and AI-driven security operations into a single platform. Its platformization strategy—encouraging customers to adopt its entire security stack rather than piecemeal tools—has made it the default enterprise choice as companies race to secure their AI deployments. No name on this list has performed better in 2026, with the stock up an eye-catching 94% year to date as of Friday's close. Palo Alto also has the strongest news sentiment score in the group, and it recently launched a Frontier AI defense program to protect enterprise AI systems. The consensus rating among 48 analysts is Moderate Buy. As with several of its peers, the valuation is now rich and the stock trades near its average target. The burden therefore shifts to its upcoming earnings report, expected around Sept. 1, to justify the enthusiasm. Institutional activity in Palo Alto has been substantial, with a sizable net inflow over the past 12 months. More than $51 billion in total institutional inflows have been recorded, compared with just $4.4 billion in outflows. Ahead of the company's all-important second-quarter report, its current institutional ownership percentage is nearly 80%. The Common Denominator Five stocks, one sector and a wave of analyst upgrades that is hard to ignore. What connects these names is a shared realization on Wall Street: Software is no longer the laggard of the AI trade but an increasingly direct beneficiary, whether through consumption-based data platforms, identity security for AI agents or observability for sprawling cloud systems. The upgrades reflect that shift in thinking. The caution, as is often the case in this market, is valuation. Several of these names have run hard and now trade near their targets, with earnings reports looming that will separate the leaders from the laggards. However, one thing remains clear: When analysts move this decisively on an entire group, it is usually a signal worth respecting.   This email is a paid sponsorship for Trading Wire, a third-party advertiser of MarketBeat. Why did I receive this email?.     This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Trading Wire. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $4,500. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Trading Wire. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Trading Wire' website for additional information about the relationship between Trading Wire and BioStem Technologies Inc. (OTC: BSEM).     If you need assistance with your newsletter, please contact MarketBeat's U.S. based support team at contact@marketbeat.com.   If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.   © 2006-2026 MarketBeat Media, LLC. 345 N Reid Pl., Suite 620, Sioux Falls, S.D. 57103-7078. U.S.A..   Read More: Buffett's Final Warning: "The Dollar Is Going to Hell" (From Decentralized Masters)